NEW YORK (Stockpickr) -- Professional traders don't just look at a stock's price moves; they also look for big changes in volume.
Major moves in volume can signal unusual activity, such as insider buying or selling -- or buying or selling by "superinvestors."
Let's take a look at several stocks rising on unusual volume today. In today's trading, these stocks are all already recording volume that is 87% or more above their average trading volume for a full day.
>>5 Technical Setups to Ride This Rally
United Therapeutics (UTHR)
is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The stock is trading up 1% at $40.14 in recent trading.
Volume: 5.2 million
Average Volume: 1.6 million
Volume % Change: 220.4%
On Tuesday, United Therapeutics announced plans to offer $210 million in senior notes and to buy back up to $212 million worth of stock.
The stock is one of the top holdings of Steven Cohen's SAC Capital
as of the most recently reported period.
Liz Claiborne (LIZ)
and its subsidiaries are engaged mainly in the design and marketing of a global portfolio of retail-based premium brands, including Juicy Couture and Kate Spade. The stock is trading up 32.6% at $6.76 in recent trading.
Volume: 15.1 million
Average Volume: 3.5 million
Volume % Change: 320.8%
On Wednesday, Liz Claiborne announced plans to sell several brands
for $328 million -- including its namesake brand, which will go to J.C. Penney (JCP)
-- to focus on higher-end brands such as Kate Spade and Juicy Couture. The company will also change its name.
Onyx Pharmaceuticals (ONXX)
is a biopharmaceutical company is engaged in the development of innovative therapies that target the molecular mechanisms that cause cancer. The stock is trading up 6% at $33.81 in recent trading.
Volume: 2.8 million
Average Volume: 901,600
Volume % Change: 214.8%
On Wednesday, Onyx and Bayer a settlement in the lawsuit over the development and marketing of the cancer drug regorafenib
in which Onyx will receive 20% royalty from Bayer on worldwide sales of the drug.